Skip to main content
. 2017 Apr 27;8(26):42761–42771. doi: 10.18632/oncotarget.17463

Table 3. Diagnostic performance of single or multiple biomarkers for the detection of pancreatic cancer.

Marker % Sensitivity at fixed 90% Specificity
Pancreatic cancer vs. Early pancreatic cancer vs.
Healthy subjects + Pancreatitis Healthy subjects Pancreatitis Healthy subjects + Pancreatitis Healthy subjects Pancreatitis
CA19-9 79.4 84.9 69.1 88.7 93.6 71.0
APOA4 27.1 16.4 51.4 32.3 22.6 50.0
APOC3 35.3 35.3 35.3 29.0 11.3 29.0
IGFBP2 30.5 30.5 30.5 35.5 35.5 35.5
TIMP1 17.7 14.7 21.6 17.7 14.5 22.6
CA199+APOA4 73.3 84.9 73.3 29.0 12.9 75.8
CA199+APOC3 71.6 84.3 71.6 40.3 40.3 72.6
CA199+IGFBP2 71.9 84.3 71.9 8.1 9.7 77.4
CA199+TIMP1 72.6 84.3 72.6 40.8 41.4 75.8
CA199+APOA4+APOC3 81.9 82.9 74.0 21.0 14.5 74.2
CA199+APOA4+IGFBP2 80.1 81.9 79.1 29.0 12.9 80.7
CA199+APOA4+TIMP1 43.5 42.5 79.5 27.4 25.8 85.5
CA199+IGFBP2+TIMP1 78.4 81.2 74.0 16.1 16.1 74.2

Abbreviations: CA 19-9, carbohydrate antigen 19-9; APOA4, apolipoprotein A-IV; APOC3, apolipoprotein CIII; IGFBP2, insulin-like growth factor binding protein 2; TIMP1, tissue inhibitor of metalloproteinase